“Sustained disease control with aflibercept 8 mg: A turning point in the management of exudative retinal disease: Expert consenus”, Ukr. j. ophthalmol. , no. 2, pp. 71–76, Apr. 2026, doi: 10.31288/Ukr.j.ophthalmol.202627176.